StockTipsArenaBeta

BUY Cipla Ltd. — ICICI Securities

BUYCipla Ltd.

byICICI SecuritiesHorizon: NA (inferred 1 year)14 May 2026via Institutional / Brokerage Research

Entry₹1,436.7Inferred
Target₹1,625
Total upside +13.11%
Stop lossNot given
CMP₹1,3955h ago
Active-2.90%+16.49%upside left 8 mo left
Follow ICICI Securities for new calls(68% target hit, 1025 closed calls)Get alertsWatch CIPLA for new buy/sell callsGet alertsSee 14 other Long-term calls on CIPLASee 40 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 9:47 pm IST
14 supporting19 neutral23 opposing
Supports the BUY call (14)

Explained: Why Morgan Stanley has the second-lowest price target on the Street for this drugmaker

NewsCnbc-Tv18·4 Sept · 3d ago

(opens in new tab)

Cipla announces exclusive US partnership with Qilu Pharma for keytruda biosimilar

NewsCnbc-Tv18·3 Sept · 3d ago

(opens in new tab)

Cipla announces an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to Keytruda (Pembrolizumab) in the US.

BSE · Company Update·3 Sept · 4d ago

(opens in new tab)

Sun Pharma, Cipla have more upside; Chinese drug deals may lower oncology costs: Systematix

NewsCnbc-Tv18·1 Sept · 6d ago

(opens in new tab)

Cipla shares gain after it inks cancer treatment drug licensing deal with Sino Biopharma arm

NewsCnbc-Tv18·1 Sept · 6d ago

(opens in new tab)
Neutral / worth noting (19)

Cipla Ltd is intimating shareholders and creditors about a notice regarding a Scheme of Amalgamation (by Absorption) of Inzpera Healthsciences Limited with Cipla Limited. The notice provides an opport

BSE · Company Update·3 Sept · 4d ago

(opens in new tab)

US FDA classifies Cipla subsidiary’s New York facility inspection as ‘Voluntary Action Indicated’

NewsCnbc-Tv18·29 Aug · 1w ago

(opens in new tab)

Cipla Pharma License Cancellation: FDA Withdraws Order After HC Raps It For Going "Overboard"

NewsNdtv-Profit·29 Aug · 1w ago

(opens in new tab)

Cipla shares slip after USFDA observations; Citi says no earnings impact, target at ₹1,700

NewsCnbc-Tv18·26 Aug · 2w ago

(opens in new tab)

Nifty, Sensex open lower; TCS, Eternal gain, Cipla, Maruti slip

NewsHbl·25 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (23)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·7 Sept · today

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field

NewsHbl·4 Sept · 3d ago

(opens in new tab)

Cipla Pharma license cancellation: FDA withdraws order after Bombay HC raps it for going 'overboard'

NewsCnbc-Tv18·29 Aug · 1w ago

(opens in new tab)

FDA Crackdown: Cipla Arm Loses Pune Drug Sales Licence For Storage Deficiencies, Illegal Ads

NewsNdtv-Profit·28 Aug · 1w ago

(opens in new tab)

Cipla gets seven USFDA observations for Pithampur plant after follow-up inspection

NewsCnbc-Tv18·25 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.